sorafenib has been researched along with Response Evaluation Criteria in Solid Tumors in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (73.91) | 24.3611 |
| 2020's | 6 (26.09) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, W; Chen, H; Fan, D; Guo, W; Han, G; Han, N; He, C; Hu, J; Jiang, D; Li, K; Li, X; Liu, L; Luo, B; Lv, Y; Niu, J; Shi, J; Sun, Y; Tie, J; Wang, E; Wang, J; Wang, Q; Wang, Z; Xia, D; Yang, K; Yang, S; Yin, Z; Yu, T; Yuan, J; Yuan, X; Zhang, C; Zhang, Z; Zhu, Y | 1 |
| abuTaleb, F; Ebian, H; El Shorbagy, S; Elbana, KA; Haggag, R; Harb, OA; Labib, HA; Mohammed, MS; Rashied, HA | 1 |
| An, D; Annunziata, CM; Cao, L; Chen, H; Choyke, P; Hays, JL; Kohn, EC; Lee, JM; Minasian, LM; Steinberg, SM; Turkbey, IB; Wright, J; Yu, M | 1 |
| Cho, EJ; Han, SW; Im, SA; Kim, H; Kim, TY; Kim, YJ; Lee, DW; Lee, JH; Lee, KH; Lee, Y; Oh, DY; Yoon, JH; Yu, SJ | 1 |
| Ding, B; Hernandez, S; Lencioni, R; Li, D; Salem, R; Sommer, N; Verret, W | 1 |
| Aoki, Y; Arai, T; Atsukawa, M; Doi, H; Fukai, M; Itokawa, N; Kanto, T; Kimura, K; Mano, Y; Mizokami, M; Osawa, Y; Shoji, H; Sugiyama, M; Taketomi, A; Yoshio, S | 1 |
| Bi, Y; Casak, S; Goldberg, KB; Jiang, X; Keegan, P; Lemery, S; Liu, J; McKee, AE; Patel, A; Pazdur, R; Pelosof, L; Pierre, V; Rodriguez, L; Zirkelbach, JF | 1 |
| Cai, MY; Chen, BH; Guo, YJ; Huang, JJ; Huang, WS; Meng, XC; Zhou, JW; Zhu, KS | 1 |
| Ahn, SH; Baek, SE; Han, KH; Jeon, MY; Kim, BK; Kim, DY; Kim, HS; Kim, SU; Lee, HW; Park, JY; Park, MS | 1 |
| Andreone, A; Badea, RI; Benevento, F; Brocchi, S; Ferrarini, A; Golfieri, R; Mastroroberto, M; Morselli-Labate, AM; Negrini, G; Piscaglia, F; Renzulli, M; Tovoli, F | 1 |
| Hirai, S; Kakinoki, N; Kamoshida, T; Ochi, M; Ohkawara, A; Ohkawara, H; Yanaka, A | 1 |
| Cho, E; Cho, SB; Choi, SK; Jun, CH; Kim, DH; Kim, S; Koh, YI; Sim, DW; Yu, J | 1 |
| Arai, M; Atsukawa, M; Azemoto, R; Chiba, T; Haga, Y; Inoue, M; Itobayashi, E; Itokawa, N; Kanayama, K; Kanda, T; Kanzaki, H; Kato, N; Kiyono, S; Kobayashi, K; Kusakabe, Y; Maeda, T; Maruta, S; Maruyama, H; Mizumoto, H; Nakamoto, S; Nakamura, M; Obu, M; Ogasawara, S; Okabe, S; Ooka, Y; Saito, T; Seki, A; Sugiura, N; Suzuki, E; Tawada, A; Yasui, S; Yokoyama, M | 1 |
| Andersson, M; Bennet, W; Cahlin, C; Eilard, MS; Geronymakis, C; Lindnér, P; Naredi, P; Rizell, M | 1 |
| Belghiti, J; Bouattour, M; Bruno, O; Castera, L; Dreyer, C; Faivre, S; Larroque, B; Raymond, E; Ronot, M; Vilgrain, V; Wassermann, J | 1 |
| Pitoia, F | 1 |
| Iguchi, T; Kato, M; Nakatani, T; Ninomiya, N; Tamada, S; Yamasaki, T | 1 |
| Ayav, A; Bronowicki, JP; Claudon, M; Gavanier, M; Laurent, V; Orry, X; Sellal, C | 1 |
| Bortlicek, Z; Buchler, T; Dusek, L; Fiala, O; Honzirkova, M; Kubackova, K; Melichar, B; Pavlik, T; Poprach, A; Slaby, O; Svoboda, M; Veskrnova, V; Vyzula, R; Zemanova, M | 1 |
| Aziz, SA; Bhat, GM; Changal, KH; Lone, AR; Mir, MH | 1 |
| Iizuka, J; Ishihara, H; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K; Yagisawa, T | 1 |
| Cheng, AL; Hocke, J; Loembé, AB; Meyer, T; Palmer, DH; Yen, CJ | 1 |
| Kong, W; Liu, G; Liu, X; Qu, J; Suo, S; Wu, G; Xu, J; Zhang, J | 1 |
1 review(s) available for sorafenib and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell): A case report and literature review.
Topics: Antineoplastic Agents; Antineoplastic Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Heart Atria; Heart Neoplasms; Humans; Killer Cells, Natural; Liver Neoplasms; Lung; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Radiotherapy, Adjuvant; Remission Induction; Response Evaluation Criteria in Solid Tumors; Sorafenib; Tumor Burden | 2018 |
9 trial(s) available for sorafenib and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Sorafenib may enhance antitumour efficacy in hepatocellular carcinoma patients by modulating the proportions and functions of natural killer cells.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Immunologic Factors; Kaplan-Meier Estimate; Killer Cells, Natural; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Sorafenib; Young Adult | 2020 |
Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Egypt; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; Metformin; Middle Aged; Prognosis; Progression-Free Survival; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Sorafenib; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2021 |
Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Interleukin-8; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Sorafenib | 2020 |
Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Sorafenib; Time Factors | 2021 |
Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Sorafenib; Tomography, X-Ray Computed | 2021 |
Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Area Under Curve; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Flow Cytometry; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Monocytes; Niacinamide; Phenylurea Compounds; Pilot Projects; Proportional Hazards Models; Prospective Studies; Receptor, TIE-2; Response Evaluation Criteria in Solid Tumors; ROC Curve; Sorafenib | 2017 |
Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Double-Blind Method; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Pyridines; Response Evaluation Criteria in Solid Tumors; Safety; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Blood Flow Velocity; Carcinoma, Hepatocellular; Drug Tolerance; Female; Follow-Up Studies; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Prospective Studies; Quality of Life; Response Evaluation Criteria in Solid Tumors; Sorafenib; Tomography, X-Ray Computed | 2019 |
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Risk Factors; Sorafenib; Time Factors; Tomography, X-Ray Computed | 2017 |
13 other study(ies) available for sorafenib and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Portal Vein; Prognosis; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Thrombosis; Young Adult | 2018 |
Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Reproducibility of Results; Republic of Korea; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Tomography, X-Ray Computed | 2018 |
Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Competence; Diagnostic Errors; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Observer Variation; Phenylurea Compounds; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Female; Foot; Hand; Humans; Incidence; Liver Neoplasms; Male; Medication Adherence; Middle Aged; Niacinamide; Pharmacists; Phenylurea Compounds; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Skin; Sorafenib; Survival Analysis; Treatment Failure | 2018 |
Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Prognosis; Pyridines; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Survival Rate | 2020 |
Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Survival Rate; Tomography, X-Ray Computed | 2014 |
Response to sorafenib treatment in advanced metastatic thyroid cancer.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Papillary; Compassionate Use Trials; Female; Follow-Up Studies; Heart Failure; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Response Evaluation Criteria in Solid Tumors; Sorafenib; Thyroglobulin; Thyroid Neoplasms; Treatment Outcome | 2014 |
Prolonging survival in metastatic renal cell carcinoma patients treated with targeted anticancer agents: a single-center experience of treatment strategy modifications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Life Style; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Pyrroles; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2015 |
CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Registries; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome; Withholding Treatment | 2016 |
Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Renal Cell; Developing Countries; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; India; Indoles; Kidney Neoplasms; Male; Middle Aged; Mucositis; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Prospective Studies; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sirolimus; Sorafenib; Sunitinib; Survival Rate; White People; Young Adult | 2016 |
Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Time Factors | 2017 |
Assessment of response to anti-angiogenic targeted therapy in pulmonary metastatic renal cell carcinoma: R2* value as a predictive biomarker.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Observer Variation; Phenylurea Compounds; Pyrroles; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; ROC Curve; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2017 |